Oculogyric crisis: a rare type of dystonia

Sara Boi, MD; Celia García-Malo, MD; Carmen Iglesias Rodríguez, MD

A 27-year-old man was admitted to our psychiatry service with psychotic symptoms. In the months preceding admission, he had experienced ideas of reference along with persecutory delusion. He also exhibited associated behavioural and affective impairment, and his relatives reported social isolation.

On examination, we observed persecutory delusion and ideas of reference. Phenomena of thought insertion, mixed insomnia, decreased appetite, apathy, anergy, and amotivational symptomatology were also present.

The patient was antipsychotic naïve. During admission, we started paliperidone PO, titrating the dose according to the patient’s symptoms until he reached the maximum dose of 18 mg/d with adequate tolerance and without notable adverse effects. Subsequently, we administered an intramuscular (IM) depot formulation, starting with 100 mg, and then 150 mg monthly for maintenance.

He experienced mild akathisia, which was corrected with prolonged-release biperiden 4 mg. He had a favourable clinical course, with adequate resolution of the delusional ideation. However, after the second administration of paliperidone 150 mg IM, the patient reported sexual dysfunction, so his antipsychotic was changed after only 2 months. Aripiprazole PO was initiated at 10 mg/d, with a progressive change to an IM depot formulation of 400 mg every 28 days. The first injection of aripiprazole was administered 29 days after the last dose of paliperidone. Later, the patient reported (more evident) akathisia, which again resolved with prolonged-release biperiden 4 mg. Subsequently, the patient reported discomfort in the orolingual region, compatible with mild orofacial dystonia. For this reason, we reduced the dose of aripiprazole IM to 300 mg, and biperiden was maintained.

The patient also reported that in the later weeks, he experienced occasional episodes of involuntary gaze deviation lasting a few seconds. One of these episodes was described by his mother as a rapid and transitory deviation of both eyes to one side, with no impairment of consciousness or convulsions.

Our initial clinical suspicion was oculogyric crisis (OGC). We ordered a brain MRI and video electroencephalography (EEG), and the results of both were normal.

Aripiprazole was discontinued and replaced with olanzapine 5 mg PO, which was chosen because of its sedative profile. The patient’s symptoms resolved completely.

An OCG is an uncommon type of focal dystonia that affects the extraocular muscles, producing a forced conjugate deviation of the eyes, more frequently upwards. The deviation may last from seconds to hours. The etiology of OGC is varied, the most common being the use of certain drugs that act as dopamine blockers, such as antipsychotics, antiiemics, antiepileptics and antidepressants (Table 1). Antipsychotics, both atypical and typical, are the drugs that have been most frequently associated with OGC. The likelihood of inducing OGC theoretically depends on blocking D2 in the nigrostriatal pathway. In a prospective investigation, OGC was reported to have an incidence of 1.8% after 3 months to 2 years of treatment with 1 or more second-generation antipsychotics.

Oculogyric crisis could also be related to other neurologic diseases (with genetic basis or associated with other movement disorders) and with the presence of focal brain lesions, generally affecting the basal ganglia or midbrain, and therefore compromising the nigrostriatal pathway. The most important differential diagnosis is frontal lobe epilepsy. Although both OGC and frontal lobe epilepsy are associated with gaze deviation, eye deviation in epilepsy is usually associated with lateral forced head version. Other related features could be speech arrest, tonic contractions of limbs, Todd paralysis, or impairment of consciousness. MRI and EEG should be performed. Sometimes, when the ultimate cause cannot be determined, antiepileptic drugs could be started; they will lead to clinical improvement when an epileptic origin exists and will have no effect on OGC.

The appearance of acute dystonia with the use of antipsychotics is more frequent in young, male patients with primary psychotic pathology and with the use of typical antipsychotics at high doses. However, there have been reported cases of OGC with atypical antipsychotics, including olanzapine, quetiapine and aripiprazole.

Table 1: Most frequently used drugs described as a potential cause of oculogyric crisis

| Antipsychotics | All, both typical and atypical can induce dystonia, hence OGC |
| Antiiemics | Metoclopramide, clebopride, ondansetron, and droperido |
| Antiepileptics | Carbamazepine, lamotrigine, gabapentin, and oxcarbazepine |
| Antidepressants | SSRI: fluoxetine, citalopram, fluvoxamine, escitalopram |
| Tricyclic: imipramine |
| Other | Cetirizine, organophosphate poisoning, tetrabenazine, L-dopa, lithium, edrophonium, cefexime, pentazocine, nifedipine, isotretinoin, phencyclidine, and salicylate poisoning |

OGC = oculogyric crisis; SSRI = selective serotonin reuptake inhibitor.
In our patient’s case, OGC was associated with the use of aripiprazole. It is a new-generation antipsychotic, acting as a partial antagonist on the mesolimbic pathway, stimulating presynaptic D2 receptors, reducing dopamine secretion. At the postsynaptic level, it acts as a partial agonist on D2, producing limited effects on dopamine in the nigrostriatal pathway and, therefore, a lower rate of extrapyramidal symptoms, estimated to be 0%–1%.7

The recognition and accurate diagnosis of OGC is usually challenging because the episodes are rarely witnessed by the doctor owing to their self-limited nature.

The use of typical or atypical antipsychotics, including new-generation antipsychotics, can cause extrapyramidal symptoms. Some extrapyramidal symptoms, such as OGC, may be difficult to recognize. Therefore, it is important to know their phenomenology and pathophysiology, for the optimal clinical management and treatment.

Affiliations: From the Psychiatry department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain (Boi, Rodriguez); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IISGM, CIBERSAM, Madrid, Spain (Boi); the Neurology department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain (García-Malo); and the Sleep Research Institute, Madrid, Spain (García-Malo, Boi).

Competing interests: None declared.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

DOI: 10.1503/jpn.210026

References

1. Barow E, Schneider SA, Bhatia KP, et al. Oculogyric crises: etiology, pathophysiology and therapeutic approaches. Parkinsonism Relat Disord 2017;36:3-9.
2. Gardner DM, Abidi S, Ursuliak Z, et al. Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a first-episode psychosis program. J Clin Psychopharmacol 2015;35:713-8.
3. Rodnitzky RL. Drug-induced movement disorders. Clin Neuropharmacol 2002;25:142-52.
4. Nebhinani N, Suthar N. Oculogyric crisis with atypical antipsychotics: a case series. Indian J Psychiatry 2017;59:499-501.
5. Varkula M, Dale R. Acute dystonic reaction after initiating aripiprazole monotherapy in a 20-year-old man. J Clin Psychopharmacol 2008;28:245-7.
6. Bhachech JT. Aripiprazole-induced oculogyric crisis (acute dystonia). J Pharmacol Pharmacother 2012;3:279-81.
7. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.